269. 化膿性無菌性関節炎・壊疽性膿皮症・アクネ症候群 Pyogenic arthritis Clinical trials / Disease details

臨床試験数 : 24 / 薬物数 : 30 - (DrugBank : 12) / 標的遺伝子数 : 15 - 標的パスウェイ数 : 105

3 trials found

diseases per page:

Showing 1 to 3 of 3 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04274166 (ClinicalTrials.gov)	May 2021	12/2/2020	Secukinumab for the Inflammatory Phase of Pyoderma Gangrenosum	The Efficacy and Safety of Secukinumab for the Inflammatory Phase of Pyoderma Gangrenosum	Pyoderma Gangrenosum	Drug: secukinumab 150 mg (2 injections per dose	Wake Forest University Health Sciences	Novartis	Withdrawn	18 Years	75 Years	All	0	Phase 2	United States
2	NCT02733094 (ClinicalTrials.gov)	April 2016	28/3/2016	Single-arm Study to Assess a Potential Effect of Anti-IL-17 (Secukinumab) in the Treatment of Pyoder ...	Single-arm Study to Assess a Potential Effect of Anti-IL-17 (Secukinumab) in the Treatment of Pyoder ...	Pyoderma Gangrenosum	Drug: Secukinumab	Technische Universität München	Novartis	Active, not recruiting	18 Years	75 Years	All	8	Phase 1/Phase 2	Germany
3	EUCTR2015-000762-65-DE (EUCTR)	09/07/2015	25/06/2015	Single-arm study to assess a potential effect of anti-IL-17 (Secukinumab) in the treatment of pyoder ...	Single-arm study to assess a potential effect of anti-IL-17 (Secukinumab) in the treatment of pyoder ...	Pyoderma gangrenosum is an autoinflammatory disease, characterized by relapsing, painful ulcers of t ...	Trade Name: Cosentyx ® Product Name: Cosentyx Product Code: EU/1/14/980/002; EU/1/14/980/003	Technische Universität München, School of Medicine, represented by Dean	NULL	Not Recruiting			Female: yes Male: yes	7	Phase 2;Phase 3	Germany

First Previous1Next Last